Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2018-04-24 | David J. Mazzo, Ph.D. was appointed as Caladrius' President and Chief Executive Officer on March 28, 2017. Dr. Mazzo was previously appointed as Caladrius’ Chief Executive Officer and as a member of the Caladrius Board on January 5, 2015. ... The Caladrius Board has concluded that Dr. Mazzo should continue serving as a director based on his pharmaceutical industry, management and scientific training and experience. ... Directors who are employees of Caladrius or its subsidiaries do not receive additional cash compensation for serving as directors. |
| 2021-04-28 | David J. Mazzo, Ph.D. was appointed as Caladrius' President and Chief Executive Officer on March 28, 2017. ... The Caladrius Board oversees our risk management. This oversight is administered primarily through the following: ... Our Compensation Committee’s review and approval of our executive officer compensation and its relationship to our business plans. ... The Science and Technology Committee consists of Drs. Davidson (Chairman), Brown, Traber, Mazzo, Mr. Klosk, Ms. Schwalm and Ms. Whitaker. ... Directors who are employees of Caladrius or its subsidiaries do not receive additional cash compensation for serving as directors. |
| 2024-04-29 | David J. Mazzo, Ph.D. was appointed as our President and Chief Executive Officer on March 28, 2017. Dr. Mazzo brings to Lisata over 40 years of experience in the pharmaceutical industry. |
Data sourced from SEC filings. Last updated: 2025-08-30